MetaCap

Genelux Corporation (GNLX)

NASDAQ: GNLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.17-0.11 (-4.82%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GNLX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$103.36M
EPS (TTM)
-$0.88
52-week range
1.77 – 5.89
Day range
2.12 – 2.37
Volume / Avg
315.92K / 333.31K
Beta
—

52-week range

$1.77$5.89

GNLX stock today

Genelux (GNLX) closed at $2.17 on Nov 20, down 4.82% (-$0.11), versus the S&P 500's 3.70% decline. Shares are 63.2% below their 52-week high of $5.89, set on Nov 28, 2025 and 22.6% above the 52-week low of $1.77, near the bottom of the past year's range. GNLX is down 50.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 56.3%.

Genelux has posted a net loss over the last twelve months (EPS of -$0.88), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Genelux

Company profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Thomas D. Zindrick J.D.
Headquarters
Westlake Village, CA
Employees
25
IPO year
2023

Financial highlights

Full financials

In fiscal 2025, Genelux generated $8,000 in revenue, up 0.0% from fiscal 2024. Genelux reported a net loss of $32.1 million, compared with a loss of $29.9 million a year earlier. Operating margin was -415175.0%.

Genelux annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue$8.00K$8.00K$170.00K$11.07M
Growth0.00%-95.29%-98.46%—
Net income$-32.15M$-29.87M$-28.30M$-5.21M
EPS (diluted)$-0.86$-0.95$-1.16$-0.57

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$18.83+767.74%

  • Strong buy 2
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $31.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.23 vs $-0.19
Surprise
-21.05%

GNLX news

All GNLX news

Genelux peers

Health Care sector
GNLX peer companies
CompanyPrice% ChgMarket capCompare
FHTXFoghorn Therapeutics Inc.1.72-3.37%$103.14Mvs GNLX
ORGOOrganogenesis Holdings Inc. Class A0.7716-2.23%$100.16Mvs GNLX
AKBAAkebia Therapeutics Inc.0.3855-8.71%$107.04Mvs GNLX
NERVMinerva Neurosciences Inc2.00-5.66%$99.67Mvs GNLX
CNTNCanton Strategic Holdings Inc.1.21-1.63%$98.78Mvs GNLX
BGMBGM Group Ltd. Class A8.130.00%$108.57Mvs GNLX
UNCYUnicycive Therapeutics Inc.3.35-5.10%$97.77Mvs GNLX
SPRBSpruce Biosciences Inc.38.00-6.15%$109.21Mvs GNLX

Indexes, lists and sector

Genelux stock FAQ

What is Genelux's stock price today?

GNLX last traded at $2.17 as of Nov 20, 4:00 PM EST, down 4.82% on the day. Prices are delayed at least 15 minutes.

Who is Genelux's CEO?

Mr. Thomas D. Zindrick J.D. is the chief executive officer of Genelux Corporation, which has about 25 employees.

What is the GNLX 52-week high?

The 52-week high for GNLX is $5.89 and the 52-week low is $1.77. The stock is currently 63.2% below its high.

Compare GNLX